Document Detail


Enalapril in the treatment of congestive heart failure.
MedLine Citation:
PMID:  1691416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Congestive heart failure (CHF) is a complex clinical syndrome affecting 1% of the U.S. population. The basic dysfunction, a lack of sufficient blood flow to the periphery, triggers reflex neurohumoral mechanisms that cause systemic vasoconstriction and sodium and water retention as the body attempts to protect vital organs. This, in turn, results in additional work for the failing heart and further deterioration. Vasodilators, in general, and angiotensin converting enzyme (ACE) inhibitors, in particular, interrupt this pathophysiology and improve hemodynamics. Enalapril, a long-acting ACE inhibitor, has been demonstrated to improve New York Heart Association (NYHA) functional class, pulmonary capillary wedge pressure, cardiac index, maximum oxygen uptake, and exercise tolerance in CHF patients. Data from a recent trial provide evidence that a group of patients with severe CHF who were treated with enalapril showed reduced heart size, reduced need for other heart-failure medication, and reduced mortality.
Authors:
T Giles
Related Documents :
7712066 - Captopril normalises systolic blood pressure in rats with hypertension induced by fetal...
9402466 - Adequate blood pressure control: perception and reality.
3063286 - Antihypertensive effect of captopril, canrenoate potassium, and atenolol. relations wit...
2404266 - Ace inhibitors. a safe option for hypertension and congestive heart failure.
1537716 - Pressure-dependent increase in lung vascular permeability to water but not protein.
25169906 - Bedside clinical and ultrasound-based approaches to the management of hemodynamic insta...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  15 Suppl 3     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1990  
Date Detail:
Created Date:  1990-05-11     Completed Date:  1990-05-11     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S6-10     Citation Subset:  IM    
Affiliation:
Department of Medicine, Tulane Medical School, New Orleans, Louisiana.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Captopril / therapeutic use
Double-Blind Method
Enalapril / therapeutic use*
Heart Failure / drug therapy*
Hemodynamics / drug effects
Humans
Physical Exertion
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
62571-86-2/Captopril; 75847-73-3/Enalapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enalapril: benefit-to-risk ratio in hypertensive patients.
Next Document:  Abdominal operations for intraabdominal metastases from extraabdominal primary tumors.